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Workplace bullying in junior doctors: questionnaire survey
Lyn Quine
In the United Kingdom a growing literature has identified workplace bullying as a major occupational stressor among health professionals. A study carried out in an NHS community trust found that 1 in 3 staff reported being bullied in the previous year, 1 while a report by the King's Fund, an independent health think tank, found that bullying, racial harassment, and discrimination were daily experiences for black and Asian doctors. In the United States several studies have reported that medical students suffer high levels of mistreatment or bullying during training, which increase with progression through medical school, spilling over into the early training years. [2] [3] [4] We report here findings from a study of workplace bullying among junior doctors in the United Kingdom.
Participants, methods, and results
An anonymous questionnaire was sent out with BMA News Review to 1000 doctors with job grades from house officer to senior registrar, randomly selected from the BMA members' mailing list. The questionnaire collected information about the participant's age, sex, job grade, and ethnic group. Participants were presented with a definition of bullying and asked to indicate whether they had been subjected to it in the past 12 months and whether they had witnessed others being bullied. They also completed a bullying scale which asked whether they had experienced 21 bullying behaviours from peers, senior staff, or managers in the past 12 months.
1
The response rate was 62%: 594 competed questionnaires were returned and 48 were returned undelivered by the post office. Not all questions were answered by all participants. Fifty four per cent (321) of the participants were house officers or senior house officers, 39% (230) registrars, 3% (18) senior registrars, and 3% (20) other junior grades. Half were men (294 v 296) and 70% (413 v 174) were white. Overall, 220 of the 594 junior doctors (37%) identified themselves as having been bullied in the past year, though 486 (84%) had in fact experienced one or more of the bullying behaviours described on the bullying scale; 407 (69%) had witnessed the bullying of others. Black and Asian doctors were more likely to report being bullied than white doctors (78 (45%) v 139 (34%); 2 = 6.3, df = 1, n = 585, P = 0.01; relative risk 1.59 (95% confidence interval 1.11 to 2.28)) and women were more likely to report being bullied than men (43% (126) v 32% (92); 2 = 7.7, df = 1, n = 588, P = 0.005; relative risk 1.61 (1.14 to 2.26); see table). Reports of bullying did not vary by job grade or age.
Comment
In this study 37% of junior doctors reported being bullied in the previous year and 84% had experienced at least one bullying behaviour. Black and Asian doctors were more likely to be bullied than other doctors. This should be a cause for concern, particularly since several recent studies show a pattern of discrimination at all levels in the medical profession from application to medical school to examination success, job application, and the allocation of distinction awards to consultants.
5 Women were more likely than men to be bullied, and this finding is consistent with a study of university employees by Bjorkvist et al. We should interpret these findings cautiously. The study relied on self reports of bullying, and a higher response rate would have been desirable. Nevertheless, the findings suggest that disturbingly high levels of bullying and mistreatment during training are part of many junior doctors' perceptions and experience.
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Contributors: LQ had the idea for the study, carried out the statistical analyses, and is the guarantor. Nevirapine is a non-nucleoside reverse transcriptase inhibitor used to reduce the viral load in HIV infection. Its side effects include hepatotoxicity, gastrointestinal symptoms, and dermatological reaction. 1 Efiravenz, another non-nucleoside reverse transcriptase inhibitor, has a similar structure to nevirapine and can cause insomnia and psychotic reactions. 1 We report three cases of neuropsychiatric sequelae to nevirapine in patients with HIV infection but no history of mental illness. Medline, Embase, and PsychLIT list no reported cases.
Within two weeks of starting nevirapine a 35 year old man developed low mood and had to stop working because of cognitive impairment and clouding of consciousness. He was admitted after taking an overdose of nevirapine and the treatment was stopped. Five days later, fearing that nursing staff would kill him, he leapt through a third floor window. As the temporal connection to his deterioration was unclear, nevirapine treatment was restarted. After a two week period of lucidity, he experienced a fluctuating course of impaired consciousness, lability of affect of treatment, and visual hallucinations. Nevirapine was withdrawn and within three weeks he was asymptomatic.
In another case, a 36 year old woman experienced delusions of persecution and infestation within two weeks of starting nevirapine treatment. Command hallucinations led to an impulsive suicide attempt. In a third case, a 42 year old woman developed persecutory delusions and depressive thoughts 10 days after starting nevirapine. Treatment with antipsychotic drugs was stopped in both of these cases after several weeks (risperidone, four weeks, and olanzapine, three weeks, respectively). Both patients remained asymptomatic, indicating that a degenerative process was not involved.
These three cases depict a delirium, an organic affective state, and an organic psychosis.
2 The time the patients started nevirapine treatment was clearly related to the evidence of symptoms, and all cases resolved on withdrawal of nevirapine. All cases were reported to the Committee on Safety of Medicines and the manufacturers.
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